Qbiotics

Executive Summary

Qbiotics is an Australian life-sciences company leveraging its proprietary Ecologic™ phenotypic screening platform to discover novel small-molecule therapeutics. The company focuses on oncology and wound healing, with its lead candidate tigilanol tiglate currently in Phase II clinical trials for soft-tissue sarcoma and head-and-neck cancer. This compound has demonstrated promising early-stage data, and the company is advancing toward pivotal readouts. Additionally, Qbiotics is progressing EBC-1013, a wound-healing candidate, into Phase I trials, expanding its pipeline beyond oncology. Founded in 2020 and publicly listed, Qbiotics has a lean operational model with 50-200 employees, positioning it for efficient development while managing capital effectively. The company's platform offers a distinct advantage in identifying novel mechanisms of action, potentially leading to first-in-class therapies. The upcoming Phase II data for tigilanol tiglate could be a major value driver, with positive results paving the way for registration-directed studies. Similarly, the Phase I initiation of EBC-1013 provides a second catalyst, albeit with earlier-stage risk. Qbiotics may also seek strategic partnerships to accelerate development and mitigate financial risks. Given the high unmet need in soft-tissue sarcoma and head-and-neck cancer, successful outcomes could position Qbiotics as a key player in oncology and wound healing. Overall, the company represents a high-risk, high-reward opportunity with near-term catalysts.

Upcoming Catalysts (preview)

• Q3 2026Phase II data readout for tigilanol tiglate in soft-tissue sarcoma70% success
• Q2 2026Phase I initiation and initial data for EBC-1013 in wound healing85% success
• Q4 2026Potential licensing or partnership agreement for tigilanol tiglate40% success